Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program (airing Monday-Friday, 6 a.m. - 9 a.m. ET). It is a fast-paced, irreverent look at the world of Wall Street, and the longest running show on the network. Kernen is based in CNBC's global headquarters in Englewood Cliffs, N.J.
Prior to his anchoring duties, Kernen was CNBC's On-Air Stock Editor and was featured throughout the business day on CNBC.
Kernen came to CNBC in the 1991 merger with Financial News Network, having joined FNN after a 10-year career as a stockbroker. After training at Merrill Lynch, he rose to the level of vice-president at both EF Hutton and Smith Barney. Focusing on small-to-medium-sized corporations, he managed corporate cash accounts and qualified retirement plans in addition to key employees' personal assets.
Kernen holds a bachelor's degree from the University of Colorado in molecular, cellular and developmental biology as well as a master's degree from Massachusetts Institute of Technology. During his graduate studies, he worked at the MIT Center for Cancer Research, one of the world's premier institutions. His work focused on mouse erythroleukemia cells and resulted in a series of publications in well-known scientific journals including CELL, Developmental Biology and Cold Spring Harbor Symposia on Quantitative Biology.
Follow Joe Kernen on Twitter
Anika Khan, Wells Fargo Securities Senior Economist, explains how low inventories and tight credit standards are keeping new home buyers at bay.
Ron Suskind, "Life, Animated" author, shares his personal story about his family's struggles with his son's autism, and reveals some startling facts from a Centers for Disease Control study that shows autism is on the rise. One in 42 boys are diagnosed with autism, reveals Suskind.
Choice is key to getting young people to pay for programming, Time Warner Chairman and CEO Jeff Bewkes tells CNBC.
Strategist Bob Doll tells CNBC it's all about the negative impact of lower oil prices and the rising dollar.
Valuations for energy companies may not have fallen far enough to spark dealmaking, two analysts tell CNBC.
The drugmaker has engaged in $100 billion of M&A in the last year, but CEO Brent Saunders says it's committed to innovation.
Get the best of CNBC in your inbox